Skip to main content

What the FDA labels say about taking them together

Cyclosporine and ubrogepant

Ubrogepant's FDA label of June 5, 2025 names cyclosporine in its drug interactions section; the cyclosporine labels PlainMeds reads (4) do not name ubrogepant. The ubrogepant label: “Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors.”

Check it at the source: the cyclosporine FDA label on DailyMed (effective August 10, 2026, Novartis Pharmaceuticals Corporation); the ubrogepant FDA label on DailyMed (effective June 5, 2025, Allergan, Inc.).

What does the cyclosporine label say about ubrogepant?

Cyclosporine's label (effective August 10, 2026) and its 3 other brand-application labels do not name ubrogepant in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Neoral), Novartis Pharmaceuticals Corporation, effective August 10, 2026 (SPL set 94461af3-11f1-4670-95d4-2965b9538ae3), via openFDA; the full label on DailyMed

What does the ubrogepant label say about cyclosporine?

Ubrogepant label, drug interactions

Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors (e.g., cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, grapefruit juice) [see Dosage and Administration ( 2.2 )].

Source: FDA drug label (UBRELVY), NDA211765 (Abbvie), as published by Allergan, Inc., effective June 5, 2025 (SPL set fd9f9458-fd96-4688-be3f-f77b3d1af6ab), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

14Cyclosporine generic labelers
0Ubrogepant generic labelers
CyclosporineUbrogepant
Labeled forOrgan transplant rejection, Rheumatoid arthritisMigraine
Boxed warningYesNo
Pharmacy cost (NADAC)$1.04 per unit 0.05% eye emulsion$109.11 per tablet 100 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?